BrainsWay Ltd. (BWAY.TA)
BrainsWay Ltd. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Jerusalem, JM, IL. The stock last traded at $4000.00, down 3.61% on the session, giving a market capitalisation of $1.61B. Its beta of 0.15 implies it has historically moved less than the broad market.
Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's primary innovation is its Deep Transcranial Magnetic Stimulation (dTMS) platform, which offers treatment for disorders including major and anxious depression, obsessive-compulsive disorder, nicotine addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatric practitioners, hospitals, and medical centers across the United States, Europe, Israel, and other international markets.
BrainsWay Ltd. is most often compared with the following Healthcare names: